Statement of Changes in Beneficial Ownership (4)
January 20 2022 - 04:31PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
| 1. Name
and Address of Reporting Person * Tessier Maude |
2. Issuer Name and Ticker or Trading
Symbol Ikena Oncology, Inc. [ IKNA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director _____
10% Owner
__X__ Officer (give title
below) _____ Other
(specify below)
Chief Business Officer |
|
(Last)
(First)
(Middle)
C/O IKENA ONCOLOGY, INC., 645 SUMMER STREET, SUITE
101 |
3. Date of Earliest Transaction (MM/DD/YYYY)
1/18/2022
|
|
(Street)
BOSTON, MA 02210
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
Amount |
(A) or (D) |
Price |
|
Common Stock |
1/18/2022 |
|
M |
|
38915 |
A |
$2.94 |
67707 |
D |
|
|
Common Stock |
1/18/2022 |
|
M |
|
24606 |
A |
$4.15 |
92313 |
D |
|
|
Common Stock |
1/18/2022 |
|
M |
|
8265 |
A |
$4.51 |
100578 |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
|
Stock Option (Right to Buy) |
$2.94 |
1/18/2022 |
|
M |
|
|
38915 |
(1) |
8/8/2028 |
Common Stock |
38915 |
$0.00 |
5560 |
D |
|
|
Stock Option (Right to Buy) |
$4.15 |
1/18/2022 |
|
M |
|
|
24606 |
(2) |
3/19/2029 |
Common Stock |
24606 |
$0.00 |
11186 |
D |
|
|
Stock Option (Right to Buy) |
$4.51 |
1/18/2022 |
|
M |
|
|
8265 |
(3) |
12/5/2029 |
Common Stock |
8265 |
$0.00 |
28963 |
D |
|
| Explanation of
Responses: |
| (1) |
25% of this option vested
and became exercisable on July 16, 2019, with the remainder vesting
in 36 substantially equal monthly installments
thereafter. |
| (2) |
25% of this option vested
and became exercisable on March 20, 2020, with the remainder
vesting in 36 substantially equal monthly installments
thereafter. |
| (3) |
25% of this option vested
and became exercisable on December 6, 2020, with the remainder
vesting in 36 substantially equal monthly installments
thereafter. |
Reporting
Owners
|
|
Reporting Owner Name / Address |
Relationships
|
|
Director |
10% Owner |
Officer |
Other |
Tessier Maude
C/O IKENA ONCOLOGY, INC.
645 SUMMER STREET, SUITE 101
BOSTON, MA 02210 |
|
|
Chief Business Officer |
|
Signatures
|
|
/s/ Douglas R. Carlson, as Attorney-in-Fact for
Maude Tessier |
|
1/20/2022 |
| **Signature of Reporting
Person |
Date |
Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From Apr 2022 to May 2022
Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From May 2021 to May 2022
